Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | FPR1 | P21462 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5234596 | 0.88 | SMN1; SMN2 (0.39) | HPGDSMN1; SMN2PKMMAPTPOLB | |
| SCHEMBL5237564 | 0.88 | SMN1; SMN2 (0.39) | HPGDSMN1; SMN2PKMMAPTPOLB | |
| SCHEMBL5234603 | 0.88 | SMN1; SMN2 (0.39) | HPGDSMN1; SMN2PKMMAPTPOLB | |
| SCHEMBL4508309 | 0.80 | HPGD (0.43) | HPGDPDE7AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL1814476 | 0.80 | HPGD (0.47) | HPGDPDE7AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL28459102 | 0.80 | MAPT (0.43) | SMN1; SMN2PKMMAPTPOLBHTT | |
| SCHEMBL1816414 | 0.77 | PKM (0.39) | HPGDSMN1; SMN2PKMMAPTPOLB | |
| SCHEMBL1608919 | 0.74 | SMN1; SMN2 (0.61) | SMN1; SMN2PKMMAPTPOLBALDH1A1 | |
| SCHEMBL21061153 | 0.74 | MAPT (0.40) | MAPTPOLBHTTPDE7AALDH1A1 | |
| SCHEMBL5237146 | 0.74 | PDE7A (0.43) | SMN1; SMN2HTTPDE7ACYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943624-B2 | Pyridinylpyrazolopyrimidinone derivatives as PDE 7 inhibitors | ASUBIO PHARMA CO. LTD. (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7943624-B2 | Pyridinylpyrazolopyrimidinone derivatives as PDE 7 inhibitors | ASUBIO PHARMA CO. LTD. (JP) | 2011-05-17 | — | — | US | disclosed |
| EP-1636235-B1 | PYRIDINYLPYRAZOLOPYRIMIDINONE DERIVATIVES AS PDE 7 INHIBITORS | ASUBIO PHARMA CO LTD (JP) | 2009-10-14 | — | — | EP | disclosed |
| US-20070270419-A1 | PYRIDINYLPYRAZOLOPYRIMIDINONE DERIVATIVES AS PDE 7 INHIBITORS | ASUBIO PHARMA CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270419-A1 | PYRIDINYLPYRAZOLOPYRIMIDINONE DERIVATIVES AS PDE 7 INHIBITORS | ASUBIO PHARMA CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270419-A1 | PYRIDINYLPYRAZOLOPYRIMIDINONE DERIVATIVES AS PDE 7 INHIBITORS | ASUBIO PHARMA CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| EP-1454897-B1 | PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY | ASUBIO PHARMA CO LTD (JP) | 2007-10-10 | — | — | EP | disclosed |
| EP-1454897-B1 | PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY | ASUBIO PHARMA CO LTD (JP) | 2007-10-10 | — | — | EP | disclosed |
| US-7268128-B2 | 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action | AUSBIO PHARMA CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
| US-7268128-B2 | 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action | AUSBIO PHARMA CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
| US-7268128-B2 | 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action | AUSBIO PHARMA CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
| US-20060128728-A1 | Pyridinylpyrazolopyrimidinone derivatives as pde 7 inhibitors | DAIICHI ASUBIO PHARMA CO., LTD (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1636235-A1 | PYRIDINYLPYRAZOLOPYRIMIDINONE DERIVATIVES AS PDE 7 INHIBITORS | Daiichi Asubio Pharma Co., Ltd. (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20050148604-A1 | Pyrazolopyrimidinone derivatives having PDE7 inhibiting action | OMEROS CORPORATION | 2005-07-07 | — | — | US | disclosed |
| WO-2004111054-A1 | PYRIDINYLPYRAZOLOPYRIMIDINONE DERIVATIVES AS PDE 7 INHIBITORS | DAIICHI ASUBIO PHARMA CO.,LTD. (JP) | 2004-12-23 | — | — | WO | disclosed |
| EP-1454897-A1 | PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY | Daiichi Suntory Pharma Co., Ltd. (JP) | 2004-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128728-A1 | Pyridinylpyrazolopyrimidinone derivatives as pde 7 inhibitors | PDE7A, PDE5A, PDE3A | HPGD 324/4885SMN1; SMN2 3162/4885PKM 1749/4885 |
| US-20070270419-A1 | PYRIDINYLPYRAZOLOPYRIMIDINONE DERIVATIVES AS PDE 7 INHIBITORS | PDE7A, PDE5A, PDE3A | HPGD 273/4885SMN1; SMN2 3197/4885PKM 1618/4885 |
| US-20050148604-A1 | Pyrazolopyrimidinone derivatives having PDE7 inhibiting action | PDE7B, PDE3B, PDE3A | HPGD 514/4885SMN1; SMN2 4062/4885PKM 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.